Most large investors were buying, yet one major fund quietly headed for the exits.
In the second quarter, institutional investors cast divergent votes of confidence in Keysight Technologies, a maker of electronic test and measurement equipment whose fortunes touch industries from semiconductors to aerospace. While most large funds quietly added to their positions and the company itself delivered earnings that surpassed expectations, one notable holder retreated sharply — a reminder that even amid consensus, markets are never truly of one mind. The stock, trading near $173 against an analyst target of $187, sits at a crossroads where solid fundamentals meet a valuation that forgives little error.
- CX Institutional's decision to cut its stake by more than half ran directly against the grain of nearly every other major fund, creating a conspicuous dissent in an otherwise bullish institutional chorus.
- Several investors moved with conviction in the opposite direction — Ballentine Partners nearly tripled its position, and Ohio's public pension fund added over 1,600 shares, signaling institutional confidence that extends well beyond speculative appetite.
- Keysight's own numbers gave the bulls ammunition: a Q2 earnings beat, 11.1% revenue growth, and forward guidance that implies an acceleration into year-end.
- JPMorgan raised its price target to $200 while others trimmed modestly, and a senior insider sold nearly $350,000 worth of shares — small signals that temper, without reversing, the prevailing optimism.
- The stock's price-to-earnings ratio of 55 looms over the narrative, a high-wire valuation that rewards continued execution but leaves almost no margin for the kind of stumble that even strong companies occasionally take.
The second quarter told two stories about Keysight Technologies at once. CX Institutional sold more than half its stake, reducing its holding to just 954 shares — a sharp, conspicuous exit that filed against the current of nearly every other major investor. Dakota Wealth added shares. TD Private Client grew its position by nearly 11 percent. The Public Employees Retirement System of Ohio picked up over 1,600 shares to hold a stake worth $15.3 million. Ballentine Partners nearly tripled its position in a single quarter. A new investor, Retireful LLC, entered the stock entirely. Taken together, institutional investors controlled 84.58 percent of outstanding shares — a figure that speaks to the depth of professional conviction in the company.
The operational backdrop gave those buyers reason for confidence. Keysight, which builds electronic design and test equipment for communications, defense, automotive, and semiconductor industries, reported Q2 earnings of $1.72 per share, beating estimates by five cents, on revenue of $1.35 billion that topped forecasts by $30 million and grew 11.1 percent year over year. JPMorgan responded by lifting its price target to $200 and rating the stock overweight. Barclays held its overweight rating but trimmed its target slightly. Bank of America raised its target but stayed neutral. The analyst consensus settled at a moderate buy with an average target of $187.38.
Insider activity added a quieter note. Senior Vice President Ingrid Estrada sold 2,000 shares in mid-September at roughly $174, a transaction that reduced her stake by less than 2 percent while leaving her with over 106,000 shares. Shares opened Monday near $173, well above the 52-week low of $121 but short of the high near $186. Management guided Q4 earnings between $1.79 and $1.85 per share, implying an acceleration that analysts had not yet fully priced in.
What emerged was a portrait of a company performing well, supported by most of the investors watching it most closely — but not all. The valuation, at 55 times earnings, demands that the momentum continue. CX Institutional's retreat and a handful of modest analyst downgrades were quiet reminders that confidence, however widespread, is never unconditional.
The institutional investment world sent conflicting signals about Keysight Technologies in the second quarter, with one major fund heading for the exits while others doubled down. CX Institutional slashed its stake by more than half, selling off 1,007 shares to leave itself with just 954 shares worth $156,000 by the time it filed with the Securities and Exchange Commission. The move stood out precisely because it ran counter to what nearly everyone else was doing.
Dakota Wealth Management, by contrast, added 140 shares to push its total to 3,615, a 4 percent increase. TD Private Client Wealth LLC went further, acquiring 409 additional shares to grow its position by 10.8 percent to 4,188 shares valued at $686,000. The Public Employees Retirement System of Ohio, one of the largest holders, picked up 1,662 shares during the quarter, bringing its total to 93,082 shares and a position worth $15.3 million. Ballentine Partners LLC made the most aggressive move, nearly tripling its stake with an additional 973 shares, a 58.9 percent jump. Retireful LLC entered the picture entirely, establishing a new position valued at $317,000. Institutional investors as a group controlled 84.58 percent of the company's outstanding stock.
The divergence in institutional behavior came against a backdrop of solid operational performance. Keysight, which makes electronic design and test equipment for communications, aerospace, defense, automotive, and semiconductor industries, reported second-quarter earnings of $1.72 per share in August, beating analyst expectations by five cents. Revenue hit $1.35 billion, topping forecasts by $30 million and climbing 11.1 percent from the same quarter a year earlier. The company's net profit margin sat at 10.36 percent, and return on equity reached 19.53 percent.
Wall Street's view of the stock remained largely constructive, though not without nuance. JPMorgan Chase lifted its price target to $200 in mid-July and rated the stock overweight. Barclays maintained an overweight rating but trimmed its target from $200 to $195 in late August. Bank of America raised its target from $175 to $179 but assigned a neutral rating. Wall Street Zen downgraded from strong buy to buy on September 20th. Across the analyst community, seven rated the stock a buy and one issued a hold, producing a consensus rating of moderate buy with an average price target of $187.38.
Insider activity offered another data point. Ingrid A. Estrada, a senior vice president, sold 2,000 shares on September 17th at an average price of $173.98, netting $347,960. The transaction reduced her stake by 1.84 percent, though she still owned 106,590 shares worth roughly $18.5 million. Insiders as a group held 0.61 percent of the company.
On the trading floor, Keysight shares opened Monday at $173.28, sitting between a 52-week low of $121.43 and a high of $186.20. The stock's 50-day moving average was $167.11 and its 200-day average $158.45. The company carried a market capitalization of $29.78 billion, a price-to-earnings ratio of 55.18, and a debt-to-equity ratio of 0.45. Management guided for fourth-quarter 2025 earnings between $1.79 and $1.85 per share, with full-year guidance at $7.09 per share. Analysts were forecasting $6.32 for the current fiscal year, suggesting the company expected to accelerate in the final quarter.
The picture that emerged was one of institutional confidence tempered by selective caution. Most large investors were buying, the company was beating its numbers, and Wall Street remained optimistic. Yet CX Institutional's sharp retreat and the modest downgrades from some analysts suggested that not everyone believed the momentum would hold indefinitely. The stock's valuation—trading at 55 times earnings—left little room for disappointment.
Notable Quotes
Keysight reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.67— Company earnings report, August 2025
Seven analysts rated the stock a buy and one issued a hold, producing a consensus rating of moderate buy— MarketBeat analyst consensus
The Hearth Conversation Another angle on the story
Why would CX Institutional cut its position in half when so many other funds were buying?
That's the puzzle. CX sold 1,007 shares while Dakota, TD Private Client, and others were accumulating. Sometimes a fund rebalances for reasons unrelated to the company's prospects—portfolio allocation, redemptions, risk management. We don't know their reasoning from the filing alone.
But the earnings were solid. Revenue up 11 percent, beat on the bottom line. Why would anyone be skeptical?
Solid doesn't mean cheap. At 55 times earnings, Keysight is pricing in a lot of future growth. The company guides to $7.09 for the full year, but analysts only forecast $6.32. That gap suggests either management is being conservative or the market is getting ahead of itself.
So the stock is expensive?
Relative to its historical multiples, yes. But Keysight operates in secular growth areas—semiconductors, aerospace, defense, communications infrastructure. The question is whether that growth justifies the price. Wall Street mostly thinks it does, but not unanimously.
What about that insider sale? Does that signal anything?
Estrada sold $348,000 worth, which is meaningful but not alarming. She still owns $18.5 million in stock. Insiders sell for many reasons—taxes, diversification, life events. One sale doesn't tell you much.
If I had to bet, would I buy or wait?
The consensus is moderate buy at $187.38, which is about 8 percent above where the stock was trading. The company is growing, profitable, and operates in industries that aren't going away. But you're paying a premium for that visibility. CX Institutional's exit suggests at least some professionals think the risk-reward has shifted.